Regeneron Reports 73% Response Rate in Ovarian Cancer Drug Trial
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowRegeneron Pharmaceuticals reported a 73% response rate in its ongoing ovarian cancer drug trial. This high response rate demonstrates promising efficacy for the treatment under investigation. The results could lead to further development and eventual market release, which may impact Regeneron's revenue potential significantly. For investors, the success of this trial could be crucial, influencing future stock performance for Regeneron (REGN).
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Regeneron Pharmaceuticals (REGN)
Regeneron is a biotechnology company known for Eylea and Dupixent.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier REGN news
- Eli Lilly (LLY) selected for FDA's PreCheck pilot program
- Stocks Moving Premarket: Regeneron, Dominion Energy, Macy's
- Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
- Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
- Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
